Telephone
Mail
Lutetium 177 (Lu-177) is a radioactive isotope that can be used to treat certain types of cancer. One of the main uses of Lu-177 is in the treatment of prostate cancer that has spread to other parts of the body (metastasized). The treatment involves injecting a compound called PSMA-617, which contains Lu-177, into the patient's bloodstream. The compound is specifically designed to target prostate-specific membrane antigen (PSMA), which is a protein that is found on the surface of prostate cancer cells. Once the compound has been injected, the Lu-177 in it will emit radiation that can kill the cancer cells.
There are several potential advantages to using Lu-177 for the treatment of prostate cancer. For one thing, it has a relatively short half-life, which means that it will decay and stop emitting radiation relatively quickly. This can help to minimize the risk of side effects from the treatment. Additionally, Lu-177 has been shown to be effective at targeting cancer cells that have spread to other parts of the body, which can make it a good option for patients with advanced prostate cancer.
Lutetium 177 PSMA treatment is typically used for patients with prostate cancer that has spread to other parts of the body (metastasized). It is typically used when other treatments, such as chemotherapy or hormone therapy, have not been effective in controlling the cancer or when the cancer has returned after previous treatment.
It is important to note that Lutetium 177 PSMA treatment is not suitable for all patients. It may not be suitable for patients with certain types of kidney or liver problems, or for women who are pregnant or breastfeeding. It is also not suitable for patients who are allergic to the compounds used in the treatment.
Your doctor will be able to advise you on whether Lutetium 177 PSMA treatment is a suitable option for you, based on your specific medical history and the stage and severity of your cancer.
There are several potential benefits to Lutetium 177 PSMA treatment for prostate cancer:
High efficacy: Lutetium 177 PSMA treatment has been shown to be effective at killing prostate cancer cells that have spread to other parts of the body.
Fewer side effects: Lutetium 177 has a relatively short half-life, which means that it will decay and stop emitting radiation relatively quickly. This can help to minimize the risk of side effects from the treatment.
Versatility: Lutetium 177 PSMA treatment can be administered in a variety of ways, including intravenous injection, intra-arterial injection, and intratumoral injection. This can make it easier for doctors to tailor the treatment to the needs of individual patients.
Good quality of life: Some studies have suggested that Lutetium 177 PSMA treatment may be associated with a good quality of life for patients. This is because it can be administered on an outpatient basis and may not cause as many side effects as other types of cancer treatment.
It is important to note that Lutetium 177 PSMA treatment is not suitable for all patients and may not be effective in all cases. Your doctor will be able to advise you on whether it is a suitable option for you, based on your specific medical history and the stage and severity of your cancer.
As with any medical treatment, Lutetium 177 PSMA treatment can cause side effects. The most common side effects of Lutetium 177 PSMA treatment are:
Nausea and vomiting: Some patients may experience nausea and vomiting after receiving the treatment. These symptoms usually resolve on their own within a few days.
Diarrhea: Some patients may experience diarrhea after receiving the treatment. This can usually be managed with medications prescribed by your doctor.
Fatigue: Many patients experience fatigue after receiving Lutetium 177 PSMA treatment. This is usually temporary and will resolve on its own over time.
Skin irritation: Some patients may experience skin irritation or rash at the injection site. This is usually mild and will resolve on its own.
Decreased blood counts: Lutetium 177 PSMA treatment may cause a temporary decrease in the number of white blood cells, red blood cells, and platelets in the blood. This can make patients more susceptible to infections, bruising, and bleeding.
It is important to note that these side effects are usually temporary and will resolve on their own over time. If you experience any side effects that are severe or persistent, you should contact your doctor for further evaluation and management.
Lutetium 177 PSMA treatment involves injecting a compound called PSMA-617, which contains the radioactive isotope Lutetium 177, into the patient's bloodstream. The compound is specifically designed to target prostate-specific membrane antigen (PSMA), which is a protein that is found on the surface of prostate cancer cells.
Once the compound has been injected, the Lutetium 177 in it will emit high-energy particles called beta particles. These beta particles can kill cancer cells by damaging their DNA and other genetic material. This can help to slow or stop the growth of the cancer.
Lutetium 177 PSMA treatment is usually administered on an outpatient basis, which means that patients can go home the same day. The length of the treatment and the number of doses required will depend on the stage and severity of the cancer and the individual patient's medical history.
Lutetium 177 PSMA treatment is primarily used for the treatment of prostate cancer that has spread to other parts of the body (metastasized). It is typically used when other treatments, such as chemotherapy or hormone therapy, have not been effective in controlling the cancer or when the cancer has returned after previous treatment.
The Lutetium 177 PSMA treatment itself can cause side effects, as I described in a previous answer. However, the test to determine whether Lutetium 177 PSMA treatment is suitable for a particular patient is generally well-tolerated and does not cause significant side effects.
The test involves injecting a small amount of a compound called PSMA-11, which contains a small amount of the radioactive isotope Lutetium 177, into the patient's bloodstream. This compound is similar to the one used in the actual treatment, but it contains a much smaller amount of Lutetium 177.
The test is typically performed on an outpatient basis, and the patient can go home the same day. Some patients may experience mild side effects, such as nausea, vomiting, or diarrhea, but these are usually temporary and will resolve on their own. If you experience any side effects that are severe or persistent, you should contact your doctor for further evaluation and management.
The number of doses of Lutetium 177 PSMA treatment that a patient will receive will depend on the stage and severity of their cancer and their individual medical history. Some patients may only need one or two doses of the treatment, while others may need more.
The treatment is usually administered on an outpatient basis, which means that patients can go home the same day. The length of the treatment and the number of doses required will depend on the stage and severity of the cancer and the individual patient's medical history. Your doctor will be able to advise you on how many doses of the treatment you will need based on your specific circumstances.
Lutetium 177 PSMA treatment is typically administered through a vein in the patient's arm (intravenous injection). The treatment is usually administered on an outpatient basis, which means that patients can go home the same day.
Before the treatment is administered, the patient will be asked to lie down on a bed or table. A healthcare professional will then clean the area where the injection will be given with an antiseptic solution and may apply a local anesthetic to numb the area.
Once the injection site is ready, the healthcare professional will inject the Lutetium 177 PSMA compound into a vein in the patient's arm using a needle and syringe. The injection may take several minutes to administer, and the patient may feel a slight sting when the needle is inserted.
After the injection is given, the patient will be asked to rest for a short period of time before being discharged. The patient may be given instructions on how to care for the injection site and may be asked to return for follow-up visits to monitor their progress.
It is important to follow your doctor's instructions carefully and to contact your doctor if you have any questions or concerns about the treatment.
The content of the page is for informational purposes only, please consult your doctor for diagnosis and treatment.
Koru Ankara Hospital
KİŞİSEL VERİLERİN İŞLENMESİ HAKKINDA AYDINLATMA/BİLGİLENDİRME
Erer Sağlık ve Eğitim Kurumları İşletmeciliği A.Ş. (“Özel Ankara Koru Hastanesi, Özel Koru Sincan Hastanesi kısaca Koru Sağlık Grubu”) olarak, kişisel verilerinizin güvenliği konusuna önem vermekteyiz. Hastalarımız tarafından paylaşılan her türlü kişisel veriyi hasta mahremiyetine özen gösterecek şekilde ve kişisel verilerinize ilişkin uygun güvenlik düzeyini temin etmeye yönelik gerekli her türlü teknik ve idari tedbiri alacak şekilde muhafaza etmekteyiz. Bu sorumluluğumuzun bilinci ile 6698 sayılı Kişisel Verilerin Korunması Kanunu (“Kanun”) ve ilgili mevzuat kapsamında Veri Sorumlusu sıfatıyla, kişisel verilerinizi aşağıda belirtilen çerçevede işlemekteyiz.
Kişisel Verilerin Toplanması, İşlenmesi ve İşleme Amaçları
Kişisel verileriniz Koru Sağlık Grubu tarafından sağlanmakta olan kamu sağlığının korunması, koruyucu hekimlik, tıbbî teşhis, tedavi ve bakım hizmetlerinin yürütülmesi, sağlık hizmetleri ile finansmanının planlanması ve yönetimi amaçlarıyla ve Koru Sağlık Grubu şirketlerinin faaliyet konularına uygun düşecek şekilde; sözlü, yazılı, görsel ya da elektronik ortamda, çağrı merkezi, internet sitesi, sözlü, yazılı ve benzeri kanallar aracılığıyla elde edilmektedir.
Bu kapsamda tüm tıbbî teşhis, muayene, tedavi ve bakım hizmetlerinin yürütülmesi için gerekli olan ve bu amaçla elde edilen kişisel sağlık verisi başta olmak üzere aşağıda sıralanmış olan;
amaçlarıyla Koru Sağlık Grubu tarafından işlenmektedir.
Kişisel Verilerin Aktarılması
Kişisel verileriniz, Kanun ve sair mevzuat kapsamında ve yukarıda yer verilen amaçlarla;
paylaşılabilecektir.
Kişisel Veri Toplamanın Yöntemi ve Hukuki Sebebi
Kişisel verileriniz, her türlü sözlü, yazılı, görsel ya da elektronik ortamda, yukarıda yer verilen amaçlar ve Koru Sağlık Grubu’nun faaliyet konusuna dahil her türlü işin yasal çerçevede yürütülebilmesi ve bu kapsamda Koru Sağlık Grubu’nun akdi ve kanuni yükümlülüklerini tam ve gereği gibi ifa edebilmesi için toplanmakta ve işlenmektedir.
Bu kapsamda sağlık verileri, Kanun’un 6. maddesi 3. fıkrasında da belirtildiği üzere kamu sağlığının korunması, koruyucu hekimlik, tıbbı teşhis, tedavi ve bakım hizmetlerinin yürütülmesi, sağlık hizmetleri ile finansmanının planlanması ve yönetimi hukuki ile, diğer kişisel verileriniz ise Kanunlarda öngörülmesi, hukuki yükümlülüğün yerine getirilmesi, bir hakkın tesisi ve kullanımı ile sözleşmenin ifası hukuki sebeplerine dayanarak işlenmektedir.
Kişisel Verilerin Korunmasına Yönelik Haklarınız
Kanun ve ilgili mevzuatlar uyarınca;
Veri Güvenliği ve Başvuru Hakkı
Koru Sağlık Grubu, kişisel verilerinizi bilgi güvenliği standartları ve prosedürleri gereğince alınması gereken tüm teknik ve idari güvenlik kontrollerine tam uygunlukla korumaktadır. Söz konusu güvenlik tedbirleri, teknolojik imkânlar da göz önünde bulundurularak muhtemel riske uygun bir düzeyde sağlanmaktadır.
Kanun kapsamındaki taleplerinizi, “www.koruhastanesi.com” web adresindeki “Kişisel Verilerin Korunması Kanunu Uyarınca Başvuru Formu” nu doldurarak;
Kızılırmak Mah. 1450. Sokak No:13 Çukurambar Ankara-TÜRKİYE adresine ıslak imzalı yazılı talep formu ile “Başhekim Sekreterliği” departmanı dikkatine Zarfına “Kişisel Verilerin Korunması Kanunu Kapsamında Bilgi Talebi” yazılarak bizzat teslim edebilir veya Noter kanalıyla gönderebilirsiniz.
“Kişisel Verilerin İşlenmesi Hakkında Açık Rıza Formu”